CAR T-Cell Therapy for Hematologic Cancers: Michael Bishop, MD

Video

The professor of medicine and director of the Hematopoietic Stem Cell Transplantation Program at University of Chicago Medicine described the impact of CAR T-cell therapy on the hematologic cancer landscape.

This content originally appeared on our sister site, Targeted Oncology.

Physicians are anticipating a first indication of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma, after the therapy has made significant impacts in patient care in areas it is approved: non-Hodgkin lymphoma and pediatric and young adult acute lymphoblastic leukemia (ALL). Other recent approvals have been made in mantle cell lymphoma.

Targeted Oncology spoke with Michael Bishop, MD, a professor of medicine and director of Hematopoietic Stem Cell Transplantation Program at University of Chicago Medicine, about the different settings where CAR T-cell therapy is used.

Starting with ALL for the pediatric population, CAR T cells have been a game changer, according to Bishop. These young patients have median overall survivals of less than 6 months, but the high response rates with CAR T are enabling them to potentially go on to an allogeneic stem cell transplant and in some cases, be free of disease.

In the non-Hodgkin lymphoma setting, there are now 3 products indicated for advanced B-cell non-Hodgkin lymphoma, which is significant for patients with totally refractory disease. There is this therapeutic option that is potentially curative. Bishop says investigators are seeing patients out to 5 years without any further therapy after receiving CAR T cells.

Recent Videos
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Chun-Yu Chen, PhD, a research scientist at Seattle Children’s Research Institute
William Chou, MD, on Targeting Progranulin With Gene Therapy for Frontotemporal Dementia
Alexandra Collin de l’Hortet, PhD, the head of therapeutics at Epic Bio
Related Content
© 2024 MJH Life Sciences

All rights reserved.